Related by context. All words. (Click for frequent words.) 85 lymphoma CTCL 82 cutaneous T 79 cell lymphoma CTCL 74 romidepsin 72 relapsed refractory multiple myeloma 71 Romidepsin 71 refractory cutaneous T 70 refractory chronic lymphocytic 70 Amrubicin 70 Cutaneous T 69 dasatinib Sprycel ® 69 phase IIb clinical 69 PNP inhibitor 69 metastatic renal cell carcinoma 69 systemic anaplastic large 69 chronic lymphocytic leukemia CLL 68 refractory Hodgkin lymphoma 68 alvespimycin 68 Acute Myeloid Leukemia AML 68 refractory acute myeloid 68 leukemia AML 68 hormone refractory prostate cancer 68 HER2 positive metastatic breast 68 hematologic malignancies 68 docetaxel Taxotere R 68 CYT# potent vascular disrupting 68 metastatic colorectal 67 relapsed multiple myeloma 67 advanced metastatic renal 67 receptor tyrosine kinase inhibitor 67 recurrent NSCLC 67 myelofibrosis 67 cetuximab Erbitux R 67 leukemia CLL 67 sorafenib tablets 67 Xanafide 67 mTOR inhibitor 67 AEG# 67 non metastatic osteosarcoma 67 forodesine 67 oral ridaforolimus 67 Azedra 67 FOLOTYN ® 67 familial amyloidotic polyneuropathy FAP 67 castrate resistant prostate cancer 67 radiation sensitizer 67 myelofibrosis polycythemia vera 67 erlotinib Tarceva ® 66 docetaxel Taxotere ® 66 Proxinium TM 66 generation purine nucleoside 66 histone deacetylase HDAC inhibitor 66 depsipeptide 66 Kit CD# positive 66 atypical Hemolytic Uremic Syndrome 66 eltrombopag 66 pan HDAC inhibitor 66 registrational trial 66 Epratuzumab 66 hypereosinophilic syndrome 66 metastatic castrate resistant 66 novel histone deacetylase 66 TELCYTA 66 sunitinib malate 66 recurrent glioblastoma multiforme 66 Voreloxin 66 relapsing remitting multiple sclerosis 66 multiple myeloma MM 66 CTCL 66 huC# DM4 66 Tarceva TM 66 refractory multiple myeloma 66 Golimumab 66 dependent kinase inhibitor 66 sorafenib Nexavar 66 gastrointestinal stromal tumors 66 B CLL 66 imatinib resistant 66 Pivotal Phase III 66 IL# PE#QQR 66 Torisel 66 phase IIb trial 66 rheumatoid arthritis psoriatic arthritis 66 Nexavar ® 65 MyVax R 65 chronic myeloid leukemia CML 65 diabetic neuropathic pain 65 unique alkylating agent 65 hepatitis C HCV 65 BAY #-# 65 EOquin 65 metastatic castration resistant 65 refractory peripheral T 65 myelodysplastic syndrome MDS 65 tanespimycin 65 Zolinza 65 Advanced Renal Cell 65 Phase #b/#a clinical 65 thymalfasin 65 Clolar 65 Genasense ® 65 stage IIIB 65 hematological malignancies 65 lintuzumab SGN 65 severe hypercholesterolemia 65 Cloretazine 65 metastatic hormone refractory 65 Sudhir Agrawal D.Phil 65 relapsed SCLC 65 Aflibercept 65 unresectable 65 ZYBRESTAT fosbretabulin 65 antibody MAb 65 R roscovitine CDK cyclin 65 Nimotuzumab 65 chronic eosinophilic leukemia 65 cetuximab Erbitux ® 65 HuMax CD4 65 dasatinib Sprycel 65 idiopathic pulmonary fibrosis IPF 65 gastrointestinal stromal tumors GIST 65 acute promyelocytic leukemia APL 65 temsirolimus 65 investigational monoclonal antibody 65 OPAXIO 65 ZYBRESTAT 65 opioid induced constipation OIC 65 Ceflatonin 65 superficial bladder cancer 65 plus gemcitabine 65 Palifosfamide 65 Alemtuzumab 65 AVASTIN 65 evaluating tivozanib 65 MAGE A3 ASCI 65 Peginterferon alfa 2b 64 oral prodrug 64 trabectedin 64 metastatic malignant 64 dextromethorphan quinidine 64 refractory AML 64 diarrhea predominant irritable 64 OMP #R# 64 Brentuximab Vedotin SGN 64 OncoVEX GM CSF 64 metastatic RCC 64 Vicinium TM 64 Campath ® 64 YONDELIS 64 luteinizing hormone releasing 64 tumors GIST 64 HGS ETR2 64 Aplidin 64 myelodysplastic myeloproliferative diseases 64 proteasome inhibitor 64 essential thrombocythemia ET 64 Seliciclib 64 imatinib Gleevec ® 64 Evoltra ® 64 Clolar ® 64 AA amyloidosis 64 pseudobulbar affect PBA 64 Annamycin 64 Vandetanib 64 R sorafenib tablets 64 nilotinib 64 Nexavar sorafenib 64 essential thrombocythemia 64 hematological cancers 64 zalutumumab 64 ISTODAX 64 Traficet EN 64 bevacizumab Avastin ® 64 ADVEXIN 64 non squamous 64 MT# MEDI 64 indolent NHL 64 Omacetaxine 64 Clevudine 64 mRCC 64 vandetanib 64 TORISEL 64 Romiplostim 64 TREANDA 64 LEUKINE 64 acute myelogenous leukemia AML 64 toenail onychomycosis 64 sunitinib Sutent ® 64 Pemetrexed 64 PEGylated anti 64 castration resistant prostate cancer 64 Tarceva erlotinib 64 hormone LHRH antagonist 64 Syndrome LEMS 64 androgen independent 64 rALLy clinical trial 64 Wafer polifeprosan 64 unresectable locally advanced 64 Fludara ® 64 autologous cellular immunotherapy 64 Fludara 64 Onalta ™ 64 reslizumab 64 FOLFOX6 64 imatinib mesylate 64 BRIM2 63 PDX pralatrexate 63 Insegia 63 Leukine ® 63 IMA# 63 Cannabinor 63 ponatinib 63 angiogenesis inhibitor 63 multi kinase inhibitor 63 PXD# 63 relapsed refractory 63 targeted radiotherapeutic 63 AAG geldanamycin analog 63 subcutaneous formulation 63 Daclizumab 63 VEGFR2 inhibitor 63 vinorelbine 63 medullary thyroid cancer 63 axitinib 63 modified glutathione analog 63 induced macular edema 63 Solazed TM 63 Zevalin R Ibritumomab 63 KRN# 63 CEQ# 63 forodesine HCl 63 zanolimumab 63 Ixempra 63 Hodgkin lymphoma NHL 63 IAP inhibitor 63 Herceptin trastuzumab 63 entinostat 63 hepatocellular carcinoma HCC 63 metastatic GIST 63 glioblastoma multiforme GBM 63 Methylnaltrexone 63 interferon gamma 1b 63 Zorbtive TM 63 investigational humanized monoclonal antibody 63 ELACYT 63 MGd 63 humanized anti 63 Elagolix 63 OMNARIS HFA 63 mapatumumab 63 leukemia ALL 63 ZOLINZA 63 Soliris TM eculizumab 63 sodium glucose cotransporter 63 refractory metastatic colorectal cancer 63 arthritis PsA 63 pediatric acute lymphoblastic 63 PROVENGE ® 63 pralatrexate 63 BENLYSTA ® 63 IAP inhibitors 63 nilotinib Tasigna ® 63 platinum refractory 63 refractory indolent non 63 myelofibrosis MF 63 refractory gout 63 docetaxel chemotherapy 63 fallopian tube cancers 63 BENLYSTA belimumab 63 elotuzumab 63 EOquin TM 63 ACTEMRA TM 63 Cloretazine R VNP#M 63 Vidaza R 63 post herpetic neuralgia PHN 63 lenalidomide Revlimid R 63 recurrent GBM 63 IgG1 monoclonal antibody 63 investigational pan BCR 63 Onrigin 63 Pegasys ® 63 unresectable recurrent 63 Istodax 63 PEGylated Fab fragment 63 Friedreich Ataxia FRDA 63 RG# [001] 63 ixabepilone 63 alefacept 63 Aplidin R 63 relapsed leukemia 63 refractory NSCLC 63 HQK 63 Phase #/#a trial 63 Dasatinib 63 Li Fraumeni Syndrome 63 refractory CTCL 63 sapacitabine 63 octreotide implant 63 KIACTA ™ 63 Zenvia TM 63 BCG refractory carcinoma 63 heavily pretreated 63 anticancer compound 63 follicular lymphoma FL 63 Gleevec resistant 63 mGluR5 negative 63 galiximab 63 metastatic renal cell 63 Apaziquone 63 metastatic colorectal cancer 63 MKC# MT 63 Lenalidomide 63 hepatocellular cancer 62 cell lymphoma PTCL 62 FOLOTYN 62 metastatic CRC 62 DU #b 62 Chronic Idiopathic Constipation 62 metastatic HRPC 62 ADP receptor antagonist 62 papillary renal cell carcinoma 62 HRPC 62 cetuximab Erbitux 62 Clofarabine 62 BRAF inhibitor 62 ganetespib 62 Ophena TM 62 PI3K/Akt pathway inhibitor 62 huN# DM1 62 JAK inhibitor 62 Phase 2b clinical 62 systemic ALCL 62 INSPIRE Trial Phase III 62 subependymal giant cell 62 Gel repository corticotropin injection 62 eosinophilic asthma 62 Sapacitabine 62 follicular non 62 Degarelix 62 Taxotere R 62 biologic therapy 62 sodium thiosulfate STS 62 T#I mutant 62 Taxotere ® 62 pediatric Crohn disease 62 R lenalidomide 62 CYC# 62 nab paclitaxel 62 Gemzar ® 62 clofarabine 62 advanced unresectable 62 myelodysplastic syndromes 62 orally administered inhibitor 62 oral Azacitidine 62 Darinaparsin 62 non alcoholic steatohepatitis 62 PEG SN# 62 AP# [003] 62 ALN TTR 62 systemic fungal infections 62 esophageal candidiasis 62 peripherally acting 62 TO AVOID PREGNANCY WHILE 62 SPRYCEL ® 62 Dacogen injection 62 ZADAXIN ® 62 Fibrillex TM 62 Onalta 62 Lubiprostone 62 Hepatocellular Carcinoma HCC 62 Pivotal Trial 62 Tasimelteon 62 Irinotecan 62 Cloretazine ® 62 Tyrima 62 Zenvia ™ 62 Pralatrexate 62 formerly LymphoStat B 62 superficial basal cell carcinoma 62 T DM1 62 relapsing forms 62 chronic myeloid 62 docetaxel Taxotere 62 Hsp# Inhibitor 62 AQ4N 62 oropharyngeal candidiasis 62 ZACTIMA 62 OvaRex ® MAb 62 mCRC 62 metastatic malignant melanoma 62 previously untreated follicular 62 paclitaxel Taxol ® 62 PD LID 62 talactoferrin 62 stage IIIb IV 62 eculizumab 62 follicular NHL 62 antibody MT# 62 HP Acthar Gel repository 62 XL# XL# 62 PRT# 62 HGS ETR1 62 hyperplasia BPH 62 adalimumab Humira 62 histone deacetylase inhibitor 62 gastrointestinal stromal tumor GIST 62 L Annamycin 62 Bortezomib 62 hormone refractory metastatic prostate 62 phase IIa clinical 62 relapsing remitting MS RRMS 62 hypoparathyroidism 62 mertansine 62 refractory chronic myeloid 62 targeting CD# 62 Triapine 62 Diabetic Macular Edema 62 vinca alkaloid 62 Aryplase 62 vidofludimus 62 bevacizumab Avastin R 62 metaglidasen 62 VELCADE melphalan 62 methylnaltrexone bromide 62 aflibercept VEGF Trap 62 Rituxan rituximab 62 ILUVIEN ® 62 alpha folate receptor 62 TELINTRA 62 NSCLC 62 lupus nephritis 62 gefitinib Iressa 62 Complicated Skin 62 imatinib Gleevec 62 GATTEX ® 62 bendamustine 62 Acute myeloid leukemia AML 62 non metastatic resectable 62 posaconazole 62 nucleoside analog 62 brivaracetam 62 chemotherapy induced neutropenia 62 ospemifene 62 Epothilone D 62 HBeAg negative 62 Yondelis ® 62 phase III isavuconazole 62 INCB# [003] 62 GW# [003] 62 selective modulator 62 orphan medicinal product 62 CB2 selective receptor agonist 62 Rebif ® 62 PKC# 61 virus HCV protease inhibitor 61 Ambrisentan 61 unresectable stage 61 albinterferon alfa 2b 61 Pirfenidone 61 Phase 2b Clinical Trial 61 CR# vcMMAE 61 MGCD# [001] 61 chimeric monoclonal antibody 61 pan histone deacetylase 61 EGFR expressing mCRC 61 advanced NSCLC 61 CD3 monoclonal antibody 61 PANVAC VF 61 MEK inhibitor 61 oropharyngeal candidiasis OPC 61 SAR# [004] 61 vemurafenib 61 MabCampath 61 Panzem R 61 Folotyn 61 Cimzia TM 61 Phenoptin 61 lintuzumab 61 Pivotal Phase 61 trastuzumab Herceptin R 61 Amigal 61 Enzastaurin 61 resistant ovarian cancer 61 crizotinib PF # 61 orally bioavailable 61 refractory PTCL 61 Ofatumumab 61 R Saizen R 61 panitumumab Vectibix 61 posterior uveitis 61 opioid induced bowel dysfunction 61 Telavancin 61 bevacizumab Avastin 61 Perifosine 61 chronic plaque psoriasis 61 lymphoid malignancies 61 KNS # 61 Pazopanib 61 selective kinase inhibitor 61 Phase IIb Trial 61 Sezary syndrome 61 nonsmall cell lung cancer 61 ALN TTR# 61 pain palliation 61 LymphoStat B belimumab 61 SCH # 61 ocular formulation 61 TNF Tumor Necrosis Factor 61 Metastatic Melanoma 61 tamibarotene 61 systemic juvenile idiopathic 61 Initiate Phase 61 Phase 2a trial 61 INCB# [001] 61 RSR# 61 carcinoid syndrome 61 relapsed CLL 61 Phase IIIb clinical 61 Ozarelix 61 developing Bicifadine serotonin 61 Revlimid lenalidomide 61 leukemia CML 61 acyclovir Lauriad R 61 pertuzumab 61 SCCHN 61 phase Ib 61 IMC A# 61 Sodium oxybate 61 Virulizin ® 61 Diffuse Large B 61 HuMax EGFr 61 Cloretazine R 61 Tamibarotene 61 proteasome inhibitor bortezomib 61 tesetaxel 61 obatoclax 61 Lenocta TM 61 HGS# 61 Raptiva ® 61 rasagiline tablets 61 thetreatment 61 HuLuc# 61 intravesical infusion therapy 61 ARCALYST 61 Arcalyst 61 Vorinostat 61 Quinamed 61 immunotherapeutic agent 61 Phase III clinical 61 rheumatoid arthritis RA psoriatic 61 chlorambucil 61 refractory acute promyelocytic 61 IV metastatic melanoma 61 hereditary deficiency 61 ON #.Na 61 Onco TCS 61 PEGylated interferon beta 1a 61 vismodegib 61 gemcitabine Gemzar ® 61 purpura ITP 61 T#I mutation 61 GTC recombinant human 61 CD4 monoclonal antibody 61 XL# anticancer compounds 61 T#I [002] 61 Plicera 61 peritumoral brain edema 61 Soliris eculizumab 61 sapropterin dihydrochloride 61 humanized monoclonal antibody 61 capecitabine Xeloda R 61 D aspartate NMDA receptor 61 ThermoDox R 61 enzastaurin 61 prostate cancer HRPC 61 Cell Lung Cancer 61 Avastin bevacizumab 61 azacitidine 61 systemic lupus erythematosus SLE 61 monotherapy 61 severe oral mucositis 61 Panzem R NCD 61 advanced carcinoid 61 forodesine hydrochloride 61 dacarbazine 61 ANYARA 61 haematological malignancies 61 GRN#L 61 Actemra tocilizumab 61 investigational compound 61 idiopathic thrombocytopenic purpura ITP 61 Inhalation Aerosol 61 Marqibo 61 adecatumumab 61 TEMODAL 61 Hodgkin lymphoma HL 61 Safinamide 61 Dapagliflozin 61 mitogen activated ERK kinase 61 EFAPROXYN 61 #I TM# 61 cell chronic lymphocytic 61 IMGN# 61 Combination REOLYSIN R 61 Azedra TM 61 tocilizumab 61 Hedgehog Pathway Inhibitor 61 metastatic gastric 61 Ocrelizumab 61 Serostim R 61 lumiliximab 61 EGFR inhibitors 61 Personalized Immunotherapy 61 dyskinesia PD LID 61 miconazole Lauriad ® 61 novel VDA molecule 61 protein tyrosine phosphatase 1B 61 dasatinib 61 JAK1 61 neuroendocrine tumors 61 alpha interferons 61 non nucleoside inhibitor 61 Troxatyl 61 amrubicin 61 M2 subunit 61 sunitinib Sutent 61 Navelbine ® 61 Fludarabine 61 Allovectin 7 ® 61 Gleevec imatinib 61 Neulasta R 61 Taxotere docetaxel 61 HCD# [002] 61 BYETTA ® 61 Phase Ib 61 PAOD 61 elacytarabine 61 VitiGam 61 AVE# 61 UPLYSO 61 biliary tract cancer 61 Intravenous CP 61 metastatic carcinoma 61 Phase Ib clinical 61 Myelodysplastic syndromes MDS 61 ZADAXIN 61 Actemra 61 carboplatin paclitaxel 61 Chemophase 61 Cetrorelix 61 RoACTEMRA 61 Lambert Eaton Myasthenic 61 registrational 61 xanthine oxidase inhibitor 60 AVONEX ® 60 acute myeloid leukemia AML 60 alkylating agent 60 Luteinizing Hormone Releasing Hormone 60 thalidomide Thalomid 60 neurogenic orthostatic hypotension 60 cediranib 60 Everolimus 60 BR.# 60 primary hypercholesterolemia 60 Camptosar ® 60 ALN HPN 60 recurrent malignant glioma 60 SUPPRELIN R LA 60 cell carcinoma RCC 60 Aurora kinase 60 pegylated interferons 60 tafamidis 60 relapsed MM 60 Zavesca R 60 ACZ# 60 Hycamtin 60 keloid scarring 60 pegfilgrastim 60 5 FU leucovorin 60 Adalimumab 60 TYZEKA 60 overactive bladder AA# 60 squamous non 60 SNT MC# 60 Abiraterone acetate 60 Jevtana 60 Tocilizumab 60 REMICADE ® 60 Forodesine HCl 60 Cell Lymphoma 60 vascular disrupting agent 60 situ CIS 60 novel topoisomerase 60 prGCD 60 indolent follicular non 60 Laquinimod 60 glufosfamide 60 LHRH receptor positive 60 CCR5 antagonist 60 Sebivo 60 belinostat 60 Cimzia ® certolizumab pegol 60 leukemia APL 60 Silodosin 60 phase IIb study 60 liposomal formulation 60 PEGINTRON TM 60 IBS C 60 Glufosfamide 60 Carfilzomib 60 Tavocept 60 ofatumumab 60 Relapsed Refractory 60 Gleevec imatinib mesylate 60 ALN PCS 60 tigecycline 60 bazedoxifene 60 homozygous familial hypercholesterolemia 60 painful diabetic neuropathy 60 prostate cancer mCRPC 60 Tasigna nilotinib 60 small lymphocytic lymphoma 60 renal cell carcinoma 60 SUTENT 60 pomalidomide 60 ALVESCO R 60 Velcade bortezomib 60 lexidronam injection 60 rHuPH# recombinant human 60 tyrosine kinase inhibitor TKI 60 Myocet 60 Zerenex 60 Leukine 60 BLP# Liposome Vaccine 60 Oral Fingolimod 60 pancreatic neuroendocrine tumors 60 Pixantrone 60 ADVEXIN p# therapy 60 Myelofibrosis 60 recurrent glioblastoma 60 idarubicin 60 noninfectious uveitis 60 CIMZIA ™ 60 TG# [003] 60 SCIg 60 Vitrasert R 60 small molecule Hedgehog 60 cancer mCRC 60 cIAI 60 TRISENOX 60 Docetaxel 60 Campath alemtuzumab 60 acute myeloid 60 Archexin 60 post operative ileus 60 TNF antagonists 60 Talabostat 60 TYKERB 60 carmustine implant 60 HDAC Inhibitor 60 LEP ETU 60 XL# XL# XL# 60 RhuDex ® 60 symptomatic BPH 60 pegylated interferon alfa 2a 60 mixed dyslipidemia 60 CDK cyclin dependent 60 Myelodysplastic Syndrome MDS 60 volociximab 60 malignant ascites 60 Initiate Clinical Trial 60 dihydrochloride 60 Application MAA 60 metastatic melanoma 60 tyrosine kinase inhibitor 60 resistant hormone refractory 60 INCB# [002] 60 Tiuxetan 60 NEBIDO R 60 Zarnestra 60 #D#C# 60 rALLy 60 Fodosine 60 doublet chemotherapy 60 tumor xenograft models 60 systemic lupus erythematosus 60 Metastatic Colorectal Cancer 60 Refractory Hodgkin Lymphoma 60 ongoing Phase 1b 60 efalizumab 60 gemcitabine chemotherapy 60 Alzhemed TM 60 vinca alkaloids 60 bortezomib Velcade R 60 relapsing multiple sclerosis 60 myeloid 60 Phase 2a clinical 60 PEG PAL 60 EDEMA3 60 Azacitidine 60 placebo controlled Phase 60 IRESSA 60 ENMD 60 Eculizumab 60 echinocandin 60 BiovaxID TM 60 haematologic malignancies 60 ACTEMRA 60 LUX Lung 60 pancreatic NET 60 Phase IIa trial 60 neovascular diseases 60 Auxilium transmucosal film 60 anticancer therapy 60 recurrent metastatic ovarian cancer 60 baminercept 60 Orphan Drug designations 60 calcineurin inhibitors 60 Targretin 60 autoantibody positive 60 QUADRAMET R 60 invasive candidiasis 60 mu opioid receptor antagonist 60 epithelial tumors 60 CA4P 60 Allovectin 7 60 rilonacept 60 myelodysplastic syndromes MDS 60 investigational immunotherapy 60 REVLIMID lenalidomide 60 Erbitux cetuximab 60 relapsed ovarian cancer 60 Dalbavancin 60 remission induction 60 ZEVALIN 60 irinotecan containing 60 voreloxin 60 pediatric glioma 60 ISTODAX ® 60 BENLYSTA TM 60 sorafenib Nexavar ® 60 ONCASPAR 60 metastatic colorectal carcinoma 60 Afatinib 60 containing granisetron 60 ara C 60 Trofex TM 60 Gliadel Wafer 60 Vidofludimus 60 vorinostat 60 L BLP# 60 Sanofi Aventis Taxotere 60 TBC# 60 alfa 2a 60 Vectibix 60 refractory metastatic 60 IV NSCLC 60 LUVENIQ 60 investigational oral inhibitor 60 ORENCIA ® 60 catheter occlusion 60 peripheral sensory neuropathy 60 Cimzia ® 60 polycythemia vera PV 60 oxypurinol 60 Abatacept 60 FRDA 60 Ph + ALL 60 everolimus tablets 60 MT#/MEDI-# 60 Factor VIIa 60 MYLOTARG 60 pirfenidone 60 kidney urologic 60 canakinumab 60 Aviptadil 60 Stedivaze 60 dirucotide MBP# 60 Treanda 60 non squamous NSCLC 60 allosteric modulator NAM 60 visilizumab 60 CBLC# 60 mGluR5 NAM 60 Meets Primary Endpoint 60 solid tumors 60 Bevacizumab 60 cell malignancies 60 post herpetic neuralgia 60 YONDELIS R 60 trastuzumab DM1 T DM1 60 alvimopan 60 Modrenal R 60 anti leukemic 60 FUSILEV enhances 60 DAVANAT 60 Phase IIb Clinical Trial 60 complement inhibitor eculizumab 60 gastrointestinal stromal tumor 60 sorafenib 60 CANCIDAS 60 Solazed ™ 60 panobinostat 60 Neulasta ® 60 chronic angina 60 pouchitis 60 Iluvien ® 60 R roscovitine 60 TheraCIM 60 Ceflatonin R 60 iobenguane 60 Oracea TM 60 temsirolimus Torisel ® 60 CTAP# Capsules 60 Gleevec Glivec 60 CD# monoclonal antibody 60 Linaclotide 60 Vilazodone 60 BCR ABL inhibitor 60 Targretin capsules 60 pegylated liposomal doxorubicin 60 recurrent ovarian cancer 60 CIMZIA TM certolizumab pegol 60 IMiDs R 60 Sutent sunitinib 60 Rituximab 60 neratinib 60 paclitaxel cisplatin 60 anthracycline taxane 60 refractory APL 59 Vidaza azacitidine 59 MabThera Rituxan 59 oral deforolimus 59 EGFR expressing 59 EGFR expressing metastatic colorectal 59 supplemental Biologics License Application 59 Parkinson disease levodopa induced 59 Marketing Authorization Application MAA 59 Blinatumomab 59 chronic myelogenous leukemia CML 59 Cimzia certolizumab pegol 59 Crizotinib 59 arsenic trioxide injection 59 chronic idiopathic thrombocytopenic purpura 59 Mepact 59 Zybrestat 59 Ranolazine 59 constipation OIC 59 5 fluorouracil leucovorin 59 VALSTAR 59 evaluating picoplatin 59 OHR/AVR# 59 grade cervical intraepithelial 59 Gefitinib 59 carfilzomib 59 secondary hyperparathyroidism 59 Belimumab 59 ELOXATIN 59 evaluating satraplatin 59 ketolide antibiotic 59 blinatumomab 59 metastatic androgen independent 59 LymphoStat B 59 bortezomib Velcade 59 DORIBAX 59 GV# [001] 59 MPS IVA 59 cognitive impairment associated 59 hepatocellular carcinoma 59 R bendamustine hydrochloride 59 apoptosis inducer 59 GVAX ® 59 Xcellerated T Cells 59 drug pipeline TAFA# 59 Exelixis XL# 59 postherpetic neuralgia 59 cell lymphoma ALCL 59 recurrent metastatic 59 ezogabine 59 HCV protease inhibitor 59 ASA# 59 SUTENT ® 59 Pegloticase 59 Certolizumab pegol 59 VPRIV 59 Raptiva R 59 mTOR mammalian target 59 ceftazidime 59 Restanza 59 R#/MEM # 59 MKC# MKC# PP 59 MYDICAR ® 59 HGS ETR1 mapatumumab 59 cytokine refractory 59 ThermoDox ® 59 Ixabepilone 59 immune idiopathic thrombocytopenic 59 CCR9 antagonist 59 BCX#